M
Madrigal Pharmaceuticals Inc (MDGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$423.96
-3.43 (-0.80%)
Market Cap: $9.93B
Last updated: Nov 17, 2026 at 11:06 AM ET
Madrigal Pharmaceuticals Inc (MDGL) Valuation Multiples
Madrigal Pharmaceuticals (MDGL) trades at 8.7x sales and 19.8x book value. Its P/B of 19.8x is above its 5-year median of 15.4x. Its forward P/E is 61.4x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 61.4x |
| Price to sales | 8.7x |
| Price to book | 19.8x |
| PEG | N/A |
| FCF yield | -1.4% |
Historical Medians
Against its 10-year medians, its P/B is 157.1% above 7.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 19.8x | 15.4x | 7.7x |
Valuation History
Over the 10 year ends shown, its P/B ranged from 3.4x in 2019 to 25.3x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $582.34 | 15.8x | 21.7x |
| 2024 | $308.57 | 37.4x | 9.0x |
| 2023 | $231.38 | N/A | 11.3x |
| 2022 | $290.25 | N/A | 25.3x |
| 2021 | $84.74 | N/A | 7.4x |
| 2020 | $111.17 | N/A | 7.2x |
| 2019 | $91.11 | N/A | 3.4x |
| 2018 | $112.72 | N/A | 3.6x |
| 2017 | $91.79 | N/A | 6.3x |
| 2016 | $14.90 | N/A | 4.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MDGL
What is MDGL's forward P/E ratio?
Madrigal Pharmaceuticals has a forward P/E ratio of 61.4x.
Is MDGL stock overvalued?
GNG's valuation label for MDGL is Undervalued.
What is MDGL's price to sales ratio?
Madrigal Pharmaceuticals has a price to sales ratio of 8.7x.
MDGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts